Tarsus Pharmaceuticals (NASDAQ:TARS) Downgraded to Hold Rating by Wall Street Zen

Tarsus Pharmaceuticals (NASDAQ:TARS) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday.

Several other research firms have also recently weighed in on TARS. Mizuho initiated coverage on Tarsus Pharmaceuticals in a research report on Thursday, November 20th. They set an “outperform” rating and a $100.00 price objective for the company. Oppenheimer boosted their target price on Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday. Barclays assumed coverage on shares of Tarsus Pharmaceuticals in a research note on Monday, December 8th. They set an “overweight” rating and a $100.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, January 22nd. Finally, Guggenheim boosted their price objective on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Tarsus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $87.00.

Tarsus Pharmaceuticals Stock Down 0.5%

Shares of TARS stock opened at $75.52 on Friday. Tarsus Pharmaceuticals has a 12-month low of $38.51 and a 12-month high of $85.25. The company has a quick ratio of 4.25, a current ratio of 3.85 and a debt-to-equity ratio of 0.21. The firm has a fifty day moving average of $72.00 and a 200-day moving average of $68.61. The company has a market capitalization of $3.21 billion, a price-to-earnings ratio of -46.62 and a beta of 0.57.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The company had revenue of $151.67 million during the quarter, compared to analyst estimates of $144.56 million. Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%. As a group, equities research analysts predict that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current fiscal year.

Insider Activity at Tarsus Pharmaceuticals

In related news, insider Dianne C. Whitfield sold 7,397 shares of the firm’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $80.10, for a total value of $592,499.70. Following the completion of the transaction, the insider directly owned 38,958 shares of the company’s stock, valued at approximately $3,120,535.80. This trade represents a 15.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bobak R. Azamian sold 6,000 shares of the stock in a transaction on Wednesday, December 24th. The shares were sold at an average price of $82.51, for a total transaction of $495,060.00. Following the completion of the sale, the chief executive officer owned 857,991 shares of the company’s stock, valued at approximately $70,792,837.41. This represents a 0.69% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 8.97% of the company’s stock.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of TARS. Jennison Associates LLC raised its stake in Tarsus Pharmaceuticals by 5.5% in the 3rd quarter. Jennison Associates LLC now owns 2,604,580 shares of the company’s stock worth $154,790,000 after purchasing an additional 136,582 shares in the last quarter. TFG Asset Management GP Ltd increased its holdings in shares of Tarsus Pharmaceuticals by 40.1% during the second quarter. TFG Asset Management GP Ltd now owns 250,000 shares of the company’s stock worth $10,128,000 after purchasing an additional 71,530 shares during the period. Capricorn Fund Managers Ltd acquired a new stake in shares of Tarsus Pharmaceuticals in the third quarter valued at approximately $14,264,000. TimesSquare Capital Management LLC bought a new stake in shares of Tarsus Pharmaceuticals in the third quarter valued at approximately $15,898,000. Finally, Jump Financial LLC boosted its stake in shares of Tarsus Pharmaceuticals by 385.9% in the second quarter. Jump Financial LLC now owns 237,117 shares of the company’s stock valued at $9,606,000 after buying an additional 188,317 shares during the period. Institutional investors own 90.01% of the company’s stock.

Key Tarsus Pharmaceuticals News

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Guggenheim set a new $90.00 price target for TARS, signaling confidence in long-term upside if the company executes on growth drivers. Guggenheim Price Target
• Positive Sentiment: Oppenheimer issued a favorable forecast for Tarsus’ stock, which may provide support if sentiment shifts back toward growth expectations. Oppenheimer Forecast
• Positive Sentiment: Tarsus announced management will participate in upcoming investor conferences — an opportunity to update investors on commercialization progress and future guidance. Investor Conferences Release
• Neutral Sentiment: Analysis pieces are debating whether the market has rerated TARS too cautiously after adoption headlines for XDEMVY, offering a counterpoint to the negative analyst actions but not delivering hard new catalysts. Yahoo Analysis
• Negative Sentiment: HC Wainwright sharply reduced near-term and multi-year EPS forecasts (Q1–Q4 2026 and FY2026–FY2029), cutting assumptions for revenue/earnings ramp — this is the primary downward pressure on the shares today. HC Wainwright Estimates Summary
• Negative Sentiment: Zacks Research downgraded TARS from “strong-buy” to “hold,” which can trigger selling from momentum/quant funds and heighten near-term caution among retail investors. Zacks Downgrade

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.